Afamelanotide · source year
5 selected, source-linked Afamelanotide records carrying a 2020 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
5 selected records.
3 represented types.
5 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04578496 at 2026-07-30T20:20:00.372Z. Its registry update date was 2020-11-19, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 32459219 at 2026-07-30T20:28:46.334Z. PubMed recorded a metadata revision date of 2020-05-29 and an Entrez history date of 2020-05-28. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory
DailyMed lists Structured Product Labeling version 3 for the reviewed Afamelanotide label family with a published date of 2020-04-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
DailyMed lists Structured Product Labeling version 2 for the reviewed Afamelanotide label family with a published date of 2020-03-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 28063031 at 2026-07-30T20:31:47.806Z. PubMed recorded a metadata revision date of 2020-03-06 and an Entrez history date of 2017-01-08. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗